Published in Obesity and Diabetes Week, October 10th, 2005
NovoLog is a rapid-acting insulin analogue which can be administered immediately before a meal. The FDA approval comes approximately 4 months before the agency's review deadline.
"The incidence of both type 1 and type 2 diabetes is increasing in children," said Peter Aurup, MD, vice president of clinical development, medical, and regulatory affairs, Novo Nordisk, Inc. "Approximately 1 in every 400-500 children and adolescents has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.